NF-κB Driven Lymphangiogenesis Impacts Kidney Function via a VEGFR-3 Mediated Pathway
JCI Insight · 2026
DOI: 10.1172/jci.insight.198992 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Arin L Melkonian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Medicine. Hauptthemen laut MEDLINE: Lymphangiogenesis, Vascular Endothelial Growth Factor Receptor-3, Kidney, Transcription Factor RelA. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, BLRD VA, NCI NIH HHS.
Abstract (Originalsprache)
The lymphatic system maintains fluid homeostasis and orchestrates immune cell trafficking throughout tissues. While extensively studied in cancer and lymphedema, its role in nonlymphoid organs, particularly the kidney, remains an emerging area of investigation. Previous research established molecular connections among NF-κB, VEGFR-3, and PROX-1 in regulating lymphatic growth during inflammation, and studies using global knockout mice revealed that the NF-κB1 subunit (p50) influences lymphatic vessel density. However, the role of RelA - a key component of the canonical NF-κB heterodimer - in regulating lymphatic growth and kidney function following acute kidney injury (AKI) remains unexplored. Using an inducible, predominantly lymphatic endothelial cell-specific RelA-knockout mouse model, we demonstrated that RelA expression in VEGFR-3+ cells is essential for VEGFR-3-driven lymphangiogenesis following AKI. Knockout mice exhibited substantially worse kidney function, altered histological features, impaired VEGFR-3-dependent lymphangiogenesis, and dysregulated immune cell trafficking compared with WT mice. Compensatory upregulation of PROX-1 and podoplanin occurred despite decreased VEGFR-3 and LYVE-1 total protein expression, suggesting complex regulatory mechanisms. Our findings suggest that RelA is a critical sensor for inflammation and regulator of protective lymphangiogenesis following kidney injury and provide insights into potential therapeutic targets for improved kidney injury outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Nephrology, Department of Medicine.
- Department of Biomedical Engineering; and.
- Division of Cardiothoracic Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.
- Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
- Birmingham Veterans Affairs Medical Center, Birmingham, Alabama, USA.
Förderung
- NIDDK NIH HHS
- BLRD VA
- NCI NIH HHS
- NIH
- VA
Zitieren
APA
Melkonian, A. L., Traylor, A. M., Zmijewska, A. A., Moore, K. H., Ghajar-Rahimi, G., Esman, S., Jiang, Y., Jang, H., Mehrara, B. J., Lee, T. C., George, J. F., & Agarwal, A. (2026). NF-κB Driven Lymphangiogenesis Impacts Kidney Function via a VEGFR-3 Mediated Pathway. JCI Insight. https://doi.org/10.1172/jci.insight.198992
Vancouver
Melkonian AL, Traylor AM, Zmijewska AA, Moore KH, Ghajar-Rahimi G, Esman S, et al. NF-κB Driven Lymphangiogenesis Impacts Kidney Function via a VEGFR-3 Mediated Pathway. JCI Insight. 2026. doi:10.1172/jci.insight.198992
BibTeX
@article{Melkonian2026,
author = {Melkonian, Arin L and Traylor, Amie M and Zmijewska, Anna A and Moore, Kyle H and Ghajar-Rahimi, Gelare and Esman, Stephanie and Jiang, Yanlin and Jang, Hani and Mehrara, Babak J and Lee, Timmy C and George, James F and Agarwal, Anupam},
title = {NF-κB Driven Lymphangiogenesis Impacts Kidney Function via a VEGFR-3 Mediated Pathway},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.198992}
}
EUVIMED